武汉禾元生物科技股份有限公司 首次公开发行股票并在科创板上市 招股意向书附录 | 序号 | 文件名称 | 页码 | | --- | --- | --- | | 1 | 发行保荐书 | 1 | | 2 | 财务报告及审计报告 | 34 | | 3 | 内部控制审计报告 | 200 | | 4 | 经注册会计师鉴证的非经常性损益明细表 | 208 | | 5 | 法律意见书 | 222 | | 6 | 律师工作报告 | 562 | | 7 | 发行人公司章程（草案） | 711 | | 8 | 中国证监会同意本次发行注册的文件 | 760 | 国泰海通证券股份有限公司 关于武汉禾元生物科技股份有限公司 首次公开发行股票并在科创板上市 之 发行保荐书 保荐机构（主承销商） 中国（上海）自由贸易试验区商城路 618 号 二〇二五年九月 1 声 明 本保荐机构及保荐代表人根据《中华人民共和国公司法》（以下简称《公司 法》）、《中华人民共和国证券法》（以下简称《证券法》）、《证券发行上市保荐业 务管理办法》（以下简称《保荐管理办法》）、《首次公开发行股票注册管理办法》 （以下简称《注册管理办法》）、《上海证券交易所科创板 ...

Core Viewpoint - The strategic financing of Junhe Alliance Biopharmaceuticals aims to enhance its product pipeline development in serious medical and consumer healthcare fields, potentially creating stronger synergies with Shiyao Guofang [2][3]. Company Overview - Junhe Alliance was established in November 2020, focusing on the development of innovative recombinant protein drugs and synthetic biology, with a comprehensive technology and product development system [2]. - The company has achieved international leading levels in the scale-up of high-end recombinant protein products, including recombinant type I/III human collagen and recombinant type A botulinum toxin [3]. Product Pipeline - The core product, recombinant human growth hormone injection, has completed Phase III clinical trials [3]. - The recombinant type A botulinum toxin has recently completed the first dosing of Phase III clinical trials for moderate to severe glabellar lines and is nearing the end of Phase II trials for upper limb spasticity post-stroke [3]. Recent Developments - At the 20th MEVOS International Medical Aesthetic Conference, Junhe Alliance showcased its latest synthetic biology research and three core product series, attracting significant interest from distributors and medical experts [3][10]. - The company has established an internationally leading innovative technology platform with independent intellectual property rights, which is expected to strengthen its industry position [12]. Future Outlook - The company aims to deepen innovation and accelerate product pipeline development and market entry, focusing on unmet clinical needs in serious and consumer healthcare [10][12]. - The partnership with Shiyao Guofang is anticipated to enhance the company's sustainable R&D capabilities and commercial progress, positioning it as a top player in the recombinant protein drug sector [10][12].